Championing Effectiveness Before Cost-Effectiveness*

JACC: Heart Failure

Volumn 4, Issue 5, 2016, Pages 376-379

  Dhruva, Sanket S ^a,b   Krumholz, Harlan M ^a,c,d,e  

^a ROBERT WOOD JOHNSON FOUNDATION   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY   (United States)

^e YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Cost effectiveness; Heart failure; Outcomes assessment; Patient readmissions; Telemonitoring

Indexed keywords

CANDESARTAN;

CARDIOVASCULAR MONITORING DEVICE; COST EFFECTIVENESS ANALYSIS; DEVICE APPROVAL; DEVICE FAILURE; DEVICE SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEART FAILURE; HOSPITALIZATION; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; LUNG ARTERY PRESSURE; LUNG ARTERY PRESSURE MONITOR; LUNG ARTERY PRESSURE MONITORING; MEDICAL DEVICE COMPLICATION; MEDICAL RESEARCH; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NEW YORK HEART ASSOCIATION CLASS; NURSING STAFF; PATIENT COMPLIANCE; PRESSURE MEASUREMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; SYSTEMATIC ERROR; TREATMENT OUTCOME; UNITED STATES; COST BENEFIT ANALYSIS; HOSPITAL READMISSION; TELEMEDICINE;

COST-BENEFIT ANALYSIS; HEART FAILURE; HUMANS; PATIENT READMISSION; TELEMEDICINE;

EID: 84962086943     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.02.001     Document Type: Editorial

References (17)

1. Adamson P.B., Abraham W.T., Aaron M., et al. CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. J Card Fail 2011, 17:3-10.
2. Abraham W.T., Adamson P.B., Bourge R.C., et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011, 377:658-666.
3. St. Jude Medical. St. Jude Medical (STJ) Mike Rousseau on Q4 2015 Results-earnings call transcript. Available at: . Accessed February 5, 2016. http://seekingalphacom/article/3840306-st-jude-medical-stj-mike-rousseau-q4-2015-results-earnings-call-transcript?page=3.
4. Centers for Medicare & Medicaid Services. New medical services and new technologies. Available at: . Accessed February 5, 2016. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html.
5. Institute for Clinical and Economic Review. CardioMEMS™ HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto™, Novartis AG) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks. December 1, 2015. Accessed February 5, 2016. http://ctaf.org/sites/default/files/u148/CHF_Final_Report_120115.pdf.
6. Sandhu A.T., Goldhaber-Fiebert J.D., Owens D.K., Turakhia M.P., Kaiser D.W., Heidenreich P.A. Cost-effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. J Am Coll Cardiol HF 2016, 4:368-375.
7. Anderson J.L., Heidenreich P.A., Barnett P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63:2304-2322.
8. Dhruva S.S., Krumholz H.M. The core value of cost-effectiveness analyses. J Am Coll Cardiol 2016, 67:39-41.
9. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
10. US Food and Drug Administration. CardioMEMS™ HF system approval order. May 28, 2014. Available at: . 2014. Accessed February 5, 2016. http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100045a.pdf.
11. Food and Drug Administration. CardioMEMS™ HF system summary of safety and effectiveness data. May 28, 2014. Available at: . Accessed February 5, 2016. http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100045b.pdf.
12. Howard J.P., Shun-Shin M.J., Hartley A., Bhatt D.L., Krum H., Francis D.P. Quantifying the 3 biases that lead to unintentional overestimation of the blood pressure-lowering effect of renal denervation. Circ Cardiovasc Qual Outcomes 2016, 9:14-22.
13. US Food and Drug Administration. FDA executive summary addendum prepared for the December 8, 2011 meeting of the Circulatory System Devices Panel, P100045, CardioMEMS Champion™ HF monitoring system, CardioMEMS, Inc. Available at: . Accessed February 5, 2016. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-adcom/documents/document/ucm282272.pdf.
14. Loh J.P., Barbash I.M., Waksman R. Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the CardioMEMS Champion Heart Failure Monitoring System. J Am Coll Cardiol 2013, 61:1571-1576.
15. US Food and Drug Administration. FDA Executive Summary. CardioMEMS Champion HF monitoring system PMA amendment, P100045, FDA and CardioMEMS panel package, prepared for the October 9, 2013, circulatory system devices panel meeting. Available at: . Accessed February 5, 2016. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM370689.pdf.
16. US Food and Drug Administration. Brief summary of the circulatory system devices panel meeting, October 9, 2013. Available at: . Accessed February 5, 2016. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM370995.pdf.
17. Abraham W.T., Stevenson L.W., Bourge R.C., Lindenfeld J.A., Bauman J.G., Adamson P.B. CHAMPION Trial Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016, 387:453-461.